About This Bench Log

What Peptide Batteries is

Peptide Batteries is a data-forward reading bench for four research peptides — GHK-Cu, MOTS-c, retatrutide, and tirzepatide — set up around a single question: what does each do to how cells produce and use energy? MOTS-c, encoded inside mitochondrial DNA and tied directly to the AMPK fuel-sensing pathway, is the lead compound and the tightest fit for that frame. Tirzepatide and retatrutide are receptor agonists that regulate glucose handling and, in retatrutide's case, energy expenditure directly. GHK-Cu sits at the frame's edge — its strongest evidence is in tissue repair, not energy metabolism, and the site says so plainly rather than force the connection.

The name is the organizing idea, not a literal claim: none of these compounds is a battery, and the site makes no claim about supplementing or "recharging" cellular energy in a person. The readings are data-forward — numbers, study designs, and effect sizes lead, and the underlying evidence carries the argument rather than a marketing conclusion. Two of the four, tirzepatide and — pending Phase 3 results — potentially retatrutide, are pursued as approved medicines; GHK-Cu is used in cosmetics without FDA drug approval; MOTS-c likewise has no FDA approval.

How it is compiled

Three principles govern this site. First, every research claim is tied to a numbered citation on the references page — peer-reviewed journal articles, clinical-trial publications, and structural or mechanistic studies, with DOIs and PubMed links where available. Second, evidence is described at the strength it was actually measured, in the population and study design that produced it: a 94-patient observational cohort is labeled as an association, not an interventional finding; a Phase 2 trial is labeled Phase 2, not treated as an approved-label result. Third, the four compound pages are cross-referenced to each other and to a single comparison page, because the same underlying questions — mechanism, evidence maturity, safety signal, regulatory status — recur across all four, just answered very differently in each case. Where a compound's fit to the site's stated cellular-energy-and-metabolism frame is loose, as with GHK-Cu, that is stated directly rather than smoothed over for consistency.

What it is not

This is no pharmacy, no clinic, no telehealth platform, and no vendor of any research chemical or medicine. It sells, sources, and brokers nothing discussed on these pages, holds no affiliate relationship with any manufacturer or supplier, and recommends no dose, schedule, or route of administration for anyone. Tirzepatide is available only through a licensed prescriber. Retatrutide is not approved and should be discussed only within a registered clinical trial. GHK-Cu's well-documented safety record is topical and cosmetic; other uses are unapproved and unstudied in humans. A clinical prescription for MOTS-c does not confer FDA approval on the medication. A reader after clinical guidance should consult a licensed healthcare provider; questions about citations or corrections belong on the contact page.